Pharma News | Biotech News | Global Pharma

With exclusive access to key industry decision makers and best-in-class proprietary data, Scrip empowers you to understand the news behind the news.

How it helps

Use Scrip’s focus on the strategic implications of global pharma news to fully understand what worldwide developments in the industry mean for your business.

With end-to-end coverage encompassing the whole of the drug discovery, development, and product life cycle value chain, Scrip delivers analysis, news and insights across multiple therapy areas and product types.

How it works

Scrip provides business-critical market and company intelligence from our global network of analysts, journalists and key opinion leaders. They cover companies across the industry, from biotech start-ups to multinational giants such as Pfizer, Sanofi and Shire, and report on fields including cardiovascular, diabetes, dermatology, influenza, and oncology.

Scrip gives you access to the latest licensing opportunities, partnership deals, R&D activity, market access insights and company developments. Your subscription also includes the Scrip 100 annual review, which tracks and analyzes the performance of over 600 companies and provides additional insights into pharma industry topics that impact your business.

Start a free trial

Scrip

IPO Update: Average Return Turns Negative For Newly Public Biopharma Firms

By Mandy Jackson 05 Oct 2021

With 88 initial public offerings in the US through the end of the third quarter of 2021, the biopharma industry is two IPOs ahead of the full-year 2020 total, but with an average return of -4% momentum may slow.

Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 04 Oct 2021

In this week's podcast edition of Five Must-Know Things: the prospects for Merck’s Acceleron acquisition; the pandemic and biotech capital in-flow; an interview with Menarini’s CEO; upcoming endocrine and metabolic product disorders; and an interview with Novartis Pharma’s president.

Scrip

Merck’s Oral Antiviral Data In COVID-19 May Change Pandemic Outlook

By Joseph Haas 01 Oct 2021

Merck/Ridgeback’s ribonucleoside analog shows nearly 50% reduction of risk for hospitalization or death in Phase III study. Firms will seek EUA in US; a contract is in place for 1.7 million courses of therapy.

Scrip

Sanofi’s Uses Latecomer COVID Data To Highlight Bigger mRNA Strategy

28 Sep 2021

The French drug maker isn’t moving its mRNA COVID-19 vaccine into Phase III, instead focusing on a GSK-partnered protein SARS-CoV-2 vaccine and applying mRNA technology elsewhere.

Scrip

Ex-Amgen CIO McKenzie: 'We All Have To Think Like Software Companies'

By Anju Ghangurde 27 Sep 2021

Amgen’s former chief information officer Diana McKenzie highlights the inroads made by technology firms in healthcare and how life science companies can adapt from them while leveraging core capabilities at scale.

Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 26 Sep 2021

In this week's podcast edition of Five Must-Know Things: an interview with the president of Novartis Pharma; Biogen highlights its pipeline; standout comparative data for Enhertu in breast cancer; Sanofi/Regeneron nip at Keytruda’s heels in first-line lung cancer; and a look at the market prospects for wet AMD.

Scrip

Scrip Asia 100

20 Sep 2021

The highly anticipated Scrip Asia 100 is back, and there are a limited number of opportunities for you to be a part of it. Don’t miss your chance to connect to APAC market leaders with a high-profile sponsorship of this essential annual financial performance ranking of pharma companies headquartered in the APAC region.

Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 06 Sep 2021

In this week's podcast edition of Five Must-Know Things: new US warnings for JAK inhibitors; strong new heart failure results for Jardiance; good head-to-head results for Pfizer in atopic dermatitis; US payers and drug exclusion lists; and a look ahead at key expected hematology launches.

Scrip

Chinese Biotechs Join COVID-19 Treatment Race With Repurposed Cancer Drugs

By Dexter Yan 18 Aug 2021

SC2108_China_COVID_Androgen_2BJ9T6J_1200

Chinese bioventures leap into the COVID cure fray as two little-known companies kick off clinical studies of androgen receptor antagonists in Brazil and the US.

Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 16 Aug 2021

In this week's podcast edition of Five Must-Know Things: a history of Alzheimer’s drug development; BioNTech looks beyond COVID-19 vaccines; gene therapy setbacks for bluebird; new promise for Roche’s Polivy in B-cell lymphoma; and rising US momentum for US drug price negotiations.

Datamonitor Healthcare, Biomedtracker, Scrip

2021 Post-ASCO Insights and Analysis

11 Aug 2021

The American Society of Clinical Oncology (ASCO) hosted its annual meeting from June 4-8 2021 and our team has the exclusive insights and analysis you can access today.

Scrip

Alzheimer’s Disease: Many Failures Before One Success

By Mandy Jackson 10 Aug 2021

For Biogen/Eisai’s success with Aduhelm, there were 93 failures in the anti-amyloid field. Scrip took a look back at how the pipeline for amyloid-targeting Alzheimer’s drugs progressed over roughly the past decade to showcase exactly how difficult the Alzheimer’s space has been.

Scrip

Oncology, Cell Therapy Developers Bag $175m In China

By Dexter Yan 10 Aug 2021

Investors continue to focus on anticancer therapies including small molecule drugs and cell therapies in China.

Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 09 Aug 2021

In this week's podcast edition of Five Must-Know Things: AstraZeneca looks to return to normality; Bayer’s hopes for Kerendia; Novartis’s plans for a new version of Zolgensma; Arcturus benefits from mRNA interest; and AbbVie changes tack in Alzheimer’s.

Scrip

Novavax Pins COVID-19 Hopes On Ex-US, Booster Markets

By Alaric DeArment 06 Aug 2021

The company is planning to file with regulators in the UK, EU, Canada, Australia and New Zealand, with an emphasis on booster shots in developed markets.

Scrip: industry news and insights

​Go behind the headlines

What's included

Below are the Feature List

Follow market developments

Go beyond the news

Hear from news makers

Ask the expert

Pharma Intelligence: latest

Latest headlines

Meet the team

Below are the Analyst Profile

Brenda Sandburg

Editor, Senior Editor

Cathy Kelly

Editor, Senior editor

Denise Peterson

Management, Editor In Chief, Pharma US

How we've helped other businesses

Related Products

Datamonitor Healthcare: data analysis and insight

Trialtrove: gold standard clinical trials intelligence

Biomedtracker: see the drug development process through analysts’ eyes

Next steps

This is Contactus Section

Request a Trial

Client Services

Pharma Report Store

Go behind the headlines